MANF Gene

MANF (Mesencephalic Astrocyte-Derived Neurotrophic Factor)

Introduction

MANF (Mesencephalic Astrocyte-Derived Neurotrophic Factor)

Introduction

The MANF gene (Mesencephalic Astrocyte-Derived Neurotrophic Factor), also known as ARMET (Arginine-rich, Mutated in Early stage Tumors), encodes a unique neurotrophic factor with distinctive mechanisms of action distinct from classical neurotrophic factors like BDNF or GDNF. Discovered in 2003, MANF has emerged as a promising therapeutic target for multiple neurodegenerative conditions, particularly [Parkinson's disease](/diseases/parkinsons-disease), [Alzheimer's disease](/diseases/alzheimers-disease), [stroke](/diseases/stroke), and [amyotrophic lateral sclerosis](/diseases/amyotrophic-lateral-sclerosis)[@lindholm2020][@cheng2023].

Unlike traditional neurotrophic factors that signal through specific receptor tyrosine kinases, MANF exerts its neuroprotective effects primarily through modulation of [endoplasmic reticulum](/entities/endoplasmic-reticulum) (ER) stress responses and direct chaperone activity. This unique mechanism positions MANF as a particularly attractive therapeutic agent for diseases characterized by protein misfolding and ER dysfunction["@yang2024"][@aparekh2021].

<div class="infobox infobox-gene">
<table>
<tr><th>Gene Symbol</th><td>MANF</td></tr>
<tr><th>Full Name</th><td>Mesencephalic Astrocyte-Derived Neurotrophic Factor</td></tr>
<tr><th>Chromosomal Location</th><td>3p21.2</td></tr>
<tr><th>NCBI Gene ID</th><td>54584</td></tr>
<tr><th>OMIM</th><td>609842</td></tr>
<tr><th>Ensembl ID</th><td>ENSG00000131791</td></tr>
<tr><th>UniProt ID</th><td>Q99986</td></tr>
<tr><th>Associated Diseases</th><td>Parkinson's Disease, Alzheimer's Disease, Stroke, ALS, Glioblastoma</td></tr>
<tr><th>Protein Length</th><td>182 amino acids</td></tr>
<tr><th>Protein Family</th><td>ARMET family</td></tr>
</table>
</div>

Gene Structure and Organization

The MANF gene spans approximately 5.2 kb and consists of 4 exons encoding a 182-amino acid protein. The gene structure reveals several important features:

• Exon 1: Encodes the signal peptide and N-terminal portion
• Exon 2-4: Encode the C-terminal secreted domain with cysteine-rich regions

• ATF4 response elements (amino acid response)
• ER stress response elements (UPRE)
• Antioxidant response elements (ARE)

• Amino acid deprivation
• ER stress
• Oxidative stress
• Ischemia
• Neuroinflammation[@petrova2022]

Protein Structure and Function

Domain Architecture

MANF possesses a distinctive bipartite structure critical for its function:

N-terminal ER Retention Domain (1-60 aa):

• Contains RTDL sequence for ER localization
• Arginine-rich region for protein-protein interactions
• Direct binding to misfolded proteins
• Interaction with BiP/GRP78 chaperone

• Four conserved cysteine residues forming disulfide bonds
• Novel protein fold distinct from other neurotrophic factors
• Neurotrophic activity region
• Receptor binding domain

Molecular Mechanisms

MANF operates through multiple molecular pathways[@zhou2022][@konovalova2020]:

1. ER Stress Modulation:

• Direct chaperone activity on misfolded proteins
• Stabilization of ER membrane integrity
• Interaction with BiP/GRP78 to regulate UPR
• Modulation of PERK, IRE1, and ATF6 pathways

• Activation promotes cell survival
• Phosphorylation of BAD
• mTORC1 activation
• Critical for dopaminergic neuron survival

• Stimulation of neuronal differentiation
• Plasticity mechanisms
• Anti-apoptotic effects

• Suppression of neuroinflammation
• Reduced cytokine production
• Protection in PD and AD models[@yang2024]

Normal Function in the Nervous System

Expression Patterns

MANF shows widespread and region-specific expression in the nervous system[@petrova2022][@shen2018]:

| Brain Region | Expression Level | Primary Cell Type |
|--------------|------------------|-------------------|
| Substantia nigra | High | Dopaminergic neurons |
| Hippocampus (CA1-CA3) | High | Pyramidal neurons |
| Cortex | Moderate-High | Pyramidal neurons, interneurons |
| Cerebellum | Moderate | Purkinje cells, granule cells |
| Spinal cord | Moderate | Motor neurons |
| Striatum | Moderate | Medium spiny neurons |

Cellular Sources:

• Neurons: Constitutive expression, upregulated by stress
• Astrocytes: Major source of secreted MANF
• Microglia: Inducible expression during inflammation

Physiological Roles

Neuroprotection:

• Protects against 6-OHDA, MPTP, rotenone toxicity
• Protects against [amyloid-beta](/proteins/amyloid-beta) oligomers
• Preserves mitochondrial membrane potential
• Maintains ATP production

• Modulates synaptic vesicle release
• Regulates dendritic spine morphology
• Promotes synaptic plasticity

• Chaperone-like activity
• UPR modulation
• Calcium homeostasis

Role in Neurodegenerative Diseases

Parkinson's Disease

MANF is highly relevant to [Parkinson's disease](/diseases/parkinsons-disease) pathogenesis[@lindholm2020][@voutilainen2015][@shen2018]:

Expression Alterations:

• MANF mRNA reduced in PD substantia nigra
• Protein levels decreased in striatum
• Correlate with disease severity

• AAV-MANF delivery protects dopaminergic neurons
• 6-OHDA lesion model shows neuroprotection
• MPTP model demonstrates attenuation of degeneration
• Reduces neuroinflammation

• Promoter variants associated with PD risk
• SNP rs12765680 correlates with earlier onset[@dan2018]

• AAV-MANF gene therapy in clinical development
• Recombinant protein delivery
• Small molecule MANF inducers

Alzheimer's Disease

MANF dysfunction contributes to [Alzheimer's disease](/diseases/alzheimers-disease) through several mechanisms[@gonzalez2017]:

Pathological Involvement:

• MANF levels reduced in AD hippocampus
• Protects against Aβ oligomer toxicity
• May enhance Aβ clearance via [autophagy](/entities/autophagy)
• Reduces ER stress in neurons with pathology

• MANF overexpression improves cognition in AD models
• Reduces amyloid plaque burden
• Protects synaptic function

Stroke and Ischemia

MANF is strongly upregulated following [cerebral ischemia](/diseases/stroke)[@airavaara2021]:

Response to Injury:

• Expression increases 4-8 hours post-infarct
• Peaks at 24-48 hours
• Continues for several days

• Reduces infarct size
• Improves functional recovery
• Promotes angiogenesis
• Protects blood-brain barrier

• ER stress protection
• Anti-apoptotic signaling
• Anti-inflammatory effects

Amyotrophic Lateral Sclerosis

In [ALS](/diseases/amyotrophic-lateral-sclerosis), MANF shows altered expression in motor neurons and astrocytes[@hu2019]:

Expression Changes:

• Elevated in ALS motor neurons
• Astrocytic MANF increased
• May reflect attempted neuroprotection

• Protects motor neurons from excitotoxicity
• Modulates astrocyte-mediated inflammation
• Gene therapy approaches under investigation

Glioblastoma

Recent research reveals MANF involvement in [glioblastoma](/diseases/glioblastoma)[@entchev2020]:

• Anti-tumor effects
• Induction of apoptosis in glioma cells
• Potential therapeutic targeting

Therapeutic Implications

Gene Therapy

AAV-mediated MANF delivery represents a promising approach[@matsuoka2019]:

Delivery Methods:

• AAV serotype 2/9 for CNS targeting
• Intraparenchymal injection
• Systemic delivery with BBB-penetrant vectors

• Sustained MANF expression
• Protected dopaminergic neurons
• Improved motor function
• No adverse effects observed

Protein Therapy

Recombinant MANF protein delivery[@liu2021]:

• Modified for BBB penetration
• Extended half-life formulations
• Direct injection or nanoparticle delivery
• Demonstrated neuroprotection in models

Small Molecule Inducers

Pharmacological upregulation of endogenous MANF:

• Valproic acid increases MANF expression
• TUDCA (tauroursodeoxycholic acid) elevates MANF
• GSK3β inhibitors enhance expression

Biomarker Potential

MANF as a biomarker for neurodegeneration[@park2021]:

• Detectable in cerebrospinal fluid
• Reduced in PD and AD patients
• Potential for disease progression monitoring

Animal Models

| Model | Key Findings | Reference |
|-------|-------------|------------|
| MANF knockout mice | Progressive dopaminergic neuron loss | Cheng 2023 |
| 6-OHDA lesion + MANF | Overexpression protects against lesion | Voutilainen 2015 |
| MPTP model + MANF | Attenuates MPTP-induced degeneration | Lindholm 2020 |
| Transgenic MANF mice | Improved motor performance | Matsuoka 2019 |
| Ischemia model + MANF | Reduced infarct size | Airavaara 2021 |

Research Directions

Current research priorities include:

Cross-References

• [MANF Protein](/proteins/manf-protein) — Protein detailed page
• [Parkinson's Disease](/diseases/parkinsons-disease) — Associated disorder
• [Alzheimer's Disease](/diseases/alzheimers-disease) — Associated disorder
• [Neurotrophic Factors](/mechanisms/neurotrophic-factors) — Pathway overview
• [Dopaminergic Neurons](/cell-types/dopaminergic-neurons) — Target cell type
• [ER Stress Pathway](/mechanisms/er-stress-pathway) — Key mechanism
• [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction-pathway) — Related pathway
• [Stroke](/diseases/stroke) — Associated disorder
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) — Associated disorder

External Resources

• [NCBI Gene: MANF](https://www.ncbi.nlm.nih.gov/gene/54584)
• [UniProt: MANF (Q99986)](https://www.uniprot.org/uniprot/Q99986)
• [Human Protein Atlas: MANF](https://www.proteinatlas.org/ENSG00000131791-MANF)
• [Ensembl: MANF](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000131791)
• [GeneCards: MANF](https://www.genecards.org/cgi-bin/carddisp.pl?gene=MANF)

Pathway Diagram

The following diagram shows the key molecular relationships involving MANF Gene discovered through SciDEX knowledge graph analysis: